Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
SEHK Growth Companies With High Insider Ownership October 2024

In This Article:

As global markets experience varied economic shifts, the Hong Kong market has been navigating its own challenges, with the Hang Seng Index recently seeing significant declines amid concerns over China's economic stimulus measures. In this environment, growth companies with high insider ownership can offer unique insights into potential resilience and alignment of interests between company leaders and shareholders.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

Laopu Gold (SEHK:6181)

36.4%

33.2%

Akeso (SEHK:9926)

20.5%

53%

Fenbi (SEHK:2469)

33.1%

22.4%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.8%

69.8%

Pacific Textiles Holdings (SEHK:1382)

11.2%

37.7%

DPC Dash (SEHK:1405)

38.1%

104.2%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

109.2%

Beijing Airdoc Technology (SEHK:2251)

29.4%

93.4%

Zhejiang Leapmotor Technology (SEHK:9863)

15%

69.7%

MicroTech Medical (Hangzhou) (SEHK:2235)

25.8%

105%

Click here to see the full list of 47 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Shanghai INT Medical Instruments

Simply Wall St Growth Rating: ★★★★★☆

Overview: Shanghai INT Medical Instruments Co., Ltd. operates in the medical instruments sector and has a market cap of HK$5.51 billion.

Operations: The company generates revenue from its Cardiovascular Interventional Business, totaling CN¥718.71 million.

Insider Ownership: 29.6%

Earnings Growth Forecast: 27.2% p.a.

Shanghai INT Medical Instruments is trading at 44.2% below its estimated fair value, indicating potential undervaluation. The company's earnings and revenue are forecast to grow significantly at 27.2% and 28.7% per year respectively, outpacing the Hong Kong market averages of 12.1% and 7.3%. Despite recent shareholder dilution, net income increased from CNY 80.5 million to CNY 100.54 million in the latest half-year results, showcasing robust financial performance amidst market challenges.

SEHK:1501 Ownership Breakdown as at Oct 2024
SEHK:1501 Ownership Breakdown as at Oct 2024

Beauty Farm Medical and Health Industry

Simply Wall St Growth Rating: ★★★★★☆

Overview: Beauty Farm Medical and Health Industry Inc. operates in the health and beauty sector, focusing on medical and wellness services, with a market cap of HK$4.05 billion.

Operations: The company's revenue is derived from Aesthetic Medical Services (CN¥851.81 million), Subhealth Medical Services (CN¥125.69 million), Beauty and Wellness Services through Direct Stores (CN¥1.14 billion), and Franchisee and Others (CN¥131.48 million).